| Abigail Catherine Yates, MFTT BA | |
|
3500 Carnegie Ave, Cleveland, OH 44115-2641 | |
| (440) 260-8300 | |
| Not Available |
| Full Name | Abigail Catherine Yates |
|---|---|
| Gender | Female |
| Speciality | Marriage & Family Therapist |
| Location | 3500 Carnegie Ave, Cleveland, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932674793 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 106H00000X | Marriage & Family Therapist | M.1800124-TRNE (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Abigail Catherine Yates, MFTT BA 434 Eastland Rd, Berea, OH 44017-1217 Ph: (440) 234-2009 | Abigail Catherine Yates, MFTT BA 3500 Carnegie Ave, Cleveland, OH 44115-2641 Ph: (440) 260-8300 |
News Archive
One day soon patients may spit in a cup, instead of bracing for a needle prick, when being tested for cancer, heart disease or diabetes.
IMS Health reported today that the size of the global market for pharmaceuticals is expected to grow nearly $300 billion over the next five years, reaching $1.1 trillion in 2014. The 5 - 8 percent compound annual growth rate during this period reflects the impact of leading products losing patent protection in developed markets, as well as strong overall growth in the world's emerging countries.
Levels of non-high-density lipoprotein cholesterol (non-HDL-C) among statin-treated patients appears to be associated with the risk of developing a major cardiovascular event, such as a heart attack or stroke, as are levels of low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B, according to a meta-analysis of data from previously published studies appearing in the March 28 issue of JAMA.
Amgen and Merck, known as MSD outside the U.S. and Canada, today announced an expanded collaboration to evaluate the efficacy and safety of talimogene laherparepvec, Amgen's investigational oncolytic immunotherapy, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in a Phase 1, open-label trial of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
› Verified 9 days ago
Andrea Venier, MFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 11401 Lorain Ave, Cleveland, OH 44111 Phone: 216-651-0360 Fax: 216-651-6491 | |
Mrs. Alexandra S Goodman, LIMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 3518 W 25th St, Cleveland, OH 44109 Phone: 216-741-2241 | |
Veronica Van Horn, Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 3500 Carnegie Ave, Cleveland, OH 44115 Phone: 440-260-8300 | |
Aqueelah Wheatley, MFT-T Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 3500 Carnegie Ave, Cleveland, OH 44115 Phone: 440-260-8300 | |
Danielle King, IMFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 3500 Carnegie Ave, Cleveland, OH 44115 Phone: 440-260-8300 | |
Sharon Marie Ulrich, LPCC, MFT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 22001 Fairmount Blvd, Cleveland, OH 44118 Phone: 216-932-2800 | |
Brittany L Blankenship, MFTT Couples Therapy Medicare: Not Enrolled in Medicare Practice Location: 3500 Carnegie Ave, Cleveland, OH 44115 Phone: 440-234-2006 |